ChartMill · Aug 19, 2026
CG Oncology (NASDAQ:CGON) Flaunts a Perfect Technical Breakout Setup
CG Oncology (CGON) earns perfect 10/10 technical and setup ratings, near highs with defined breakout entry—top breakout setup stock.
CG
NASDAQ · CGON
CG Oncology, Inc. Common stock
Healthcare · Biotechnology
$63.82
Up+$0.56 (+0.89%)
Updated Oct 11, 2026, 8:44 AM
SID Score
5.3/10
Composite research score
Smart Money
61/100
Neutral
- Market cap
- 3.12B
- P/E ratio
- -29.65
- Dividend yield
- 0.00%
- 52-week range
- $35.80 – $80.97
- Volume
- 516.54K
- Avg. volume
- 990.79K
Price performance · CGON
CGON price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 9, 2026
CGON closed at $63.82 after 20 trading sessions, down 13.51% for the selected period.
- Last close
- $63.82
- Period change
- -13.51%
- Period low
- $62.38
- Period high
- $78.25
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 9, 2026 | $62.97 | $65.18 | $62.88 | $63.82 | 516.54K |
| Oct 8, 2026 | $61.65 | $63.71 | $61.11 | $63.26 | 910.31K |
| Oct 7, 2026 | $62.68 | $63.64 | $61.90 | $62.38 | 621.82K |
| Oct 6, 2026 | $69.17 | $69.17 | $63.19 | $63.64 | 774.38K |
| Oct 5, 2026 | $67.60 | $68.95 | $65.71 | $68.71 | 788.35K |
| Oct 2, 2026 | $69.35 | $69.73 | $66.61 | $67.38 | 1.54M |
| Oct 1, 2026 | $70.38 | $71.268 | $68.32 | $68.35 | 984.87K |
| Sep 30, 2026 | $70.34 | $73.16 | $69.23 | $70.89 | 1.33M |
| Sep 29, 2026 | $69.56 | $70.68 | $68.26 | $70.52 | 1.04M |
| Sep 28, 2026 | $66.96 | $69.94 | $66.01 | $69.61 | 1.76M |
| Sep 25, 2026 | $69.32 | $70.0525 | $66.7601 | $67.15 | 1.18M |
| Sep 24, 2026 | $73.10 | $73.44 | $68.15 | $68.76 | 1.44M |
| Sep 23, 2026 | $76.87 | $77.79 | $71.86 | $73.36 | 830.95K |
| Sep 22, 2026 | $78.31 | $80.6299 | $76.25 | $77.74 | 1.64M |
| Sep 21, 2026 | $75.74 | $78.465 | $74.22 | $78.25 | 1.12M |
| Sep 18, 2026 | $75.87 | $75.87 | $72.82 | $74.62 | 1.78M |
| Sep 17, 2026 | $75.00 | $76.50 | $74.43 | $75.62 | 894.29K |
| Sep 16, 2026 | $72.66 | $74.59 | $72.66 | $74.12 | 795.65K |
| Sep 15, 2026 | $74.13 | $74.13 | $72.4781 | $72.55 | 1.04M |
| Sep 14, 2026 | $72.30 | $74.67 | $71.78 | $73.79 | 829.92K |
Latest CGON news
The latest Smart Investors Daily articles mentioning CGON.
Stock researchCompany · Overview
Company
Market Activity
Research & News
CGON research
Overview
Company profile and research snapshot.
Company profile
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $69.50
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 7, 2026 | Piper Sandler | Overweight | — |
| Aug 7, 2026 | RBC Capital | Outperform | — |
| Aug 7, 2026 | Truist Securities | Buy | — |
| May 19, 2026 | Wolfe Research | Peer Perform | — |
| May 18, 2026 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Feb 27, 2026
What Analysts Are Saying About CG Oncology Stock
Benzinga · Feb 27, 2026
HC Wainwright & Co. Maintains Buy on CG Oncology, Raises Price Target to $80
HC Wainwright & Co. analyst Andres Y. Maldonado maintains CG Oncology (NASDAQ:CGON) with a Buy and raises the price target from $75 to $80.
Benzinga · Feb 27, 2026
CG Oncology Q4 Earnings Report: What Investors Need to Know
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
